Topline overall survival results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy.
Fewer than one in five eligible individuals in the United States are up-to-date with recommended lung cancer screening, according to a study led by American Cancer Society researchers.
